LU86405A1 - Derive antipsychotique du benzisothiazole s-oxyde - Google Patents

Derive antipsychotique du benzisothiazole s-oxyde Download PDF

Info

Publication number: LU86405A1
Authority: LU; Luxembourg
Prior art keywords: compound; bmy; pharmaceutically acceptable; acid; formula
Prior art date: 1985-04-24

Application number

LU86405A

Other languages

English (en)

French (fr)

Original Assignee

Bristol Myers Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1985-04-24

Filing date

1986-04-23

Publication date

1986-11-05

1986-04-23 Application filed by Bristol Myers Co filed Critical Bristol Myers Co

1986-11-05 Publication of LU86405A1 publication Critical patent/LU86405A1/fr

Links

230000000561 anti-psychotic effect Effects 0.000 title claims description 12
KANAPVJGZDNSCZ-UHFFFAOYSA-N 1,2-benzothiazole 1-oxide Chemical class C1=CC=C2S(=O)N=CC2=C1 KANAPVJGZDNSCZ-UHFFFAOYSA-N 0.000 title description 2
150000001875 compounds Chemical class 0.000 claims description 35
239000002253 acid Substances 0.000 claims description 14
150000003839 salts Chemical class 0.000 claims description 13
239000000203 mixture Substances 0.000 claims description 12
238000000034 method Methods 0.000 claims description 8
239000008194 pharmaceutical composition Substances 0.000 claims description 6
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 5
238000006243 chemical reaction Methods 0.000 claims description 5
229910052500 inorganic mineral Inorganic materials 0.000 claims description 5
239000011707 mineral Substances 0.000 claims description 5
241000124008 Mammalia Species 0.000 claims description 4
238000002360 preparation method Methods 0.000 claims description 4
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 3
238000007910 systemic administration Methods 0.000 claims description 3
208000028017 Psychotic disease Diseases 0.000 claims description 2
150000007513 acids Chemical class 0.000 claims description 2
239000002552 dosage form Substances 0.000 claims description 2
229910017604 nitric acid Inorganic materials 0.000 claims description 2
239000012467 final product Substances 0.000 claims 1
230000000694 effects Effects 0.000 description 10
239000003795 chemical substances by application Substances 0.000 description 9
238000012360 testing method Methods 0.000 description 8
241000700159 Rattus Species 0.000 description 7
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
208000009132 Catalepsy Diseases 0.000 description 5
206010047853 Waxy flexibility Diseases 0.000 description 5
239000003814 drug Substances 0.000 description 5
229940079593 drug Drugs 0.000 description 5
230000000144 pharmacologic effect Effects 0.000 description 5
239000007787 solid Substances 0.000 description 5
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
238000001727 in vivo Methods 0.000 description 4
WEVYAHXRMPXWCK-UHFFFAOYSA-N methyl cyanide Natural products CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 4
230000001962 neuropharmacologic effect Effects 0.000 description 4
229920001223 polyethylene glycol Polymers 0.000 description 4
239000000126 substance Substances 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
239000000164 antipsychotic agent Substances 0.000 description 3
238000011156 evaluation Methods 0.000 description 3
230000001747 exhibiting effect Effects 0.000 description 3
230000009931 harmful effect Effects 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
239000007788 liquid Substances 0.000 description 3
239000002207 metabolite Substances 0.000 description 3
239000003176 neuroleptic agent Substances 0.000 description 3
230000000701 neuroleptic effect Effects 0.000 description 3
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 3
239000000243 solution Substances 0.000 description 3
150000003462 sulfoxides Chemical class 0.000 description 3
MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 3
229960000894 sulindac Drugs 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
CSNIZNHTOVFARY-UHFFFAOYSA-N 1,2-benzothiazole Chemical compound C1=CC=C2C=NSC2=C1 CSNIZNHTOVFARY-UHFFFAOYSA-N 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
206010042008 Stereotypy Diseases 0.000 description 2
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 2
229960004046 apomorphine Drugs 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
230000003291 dopaminomimetic effect Effects 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
238000005259 measurement Methods 0.000 description 2
230000002503 metabolic effect Effects 0.000 description 2
235000010755 mineral Nutrition 0.000 description 2
230000003647 oxidation Effects 0.000 description 2
238000007254 oxidation reaction Methods 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
235000010356 sorbitol Nutrition 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
239000006188 syrup Substances 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
KTZQTRPPVKQPFO-UHFFFAOYSA-N 1,2-benzoxazole Chemical compound C1=CC=C2C=NOC2=C1 KTZQTRPPVKQPFO-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
206010010774 Constipation Diseases 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
206010022998 Irritability Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
206010031127 Orthostatic hypotension Diseases 0.000 description 1
206010033557 Palpitations Diseases 0.000 description 1
ATTZFSUZZUNHBP-UHFFFAOYSA-N Piperonyl sulfoxide Chemical class CCCCCCCCS(=O)C(C)CC1=CC=C2OCOC2=C1 ATTZFSUZZUNHBP-UHFFFAOYSA-N 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
235000011054 acetic acid Nutrition 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
208000013404 behavioral symptom Diseases 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000036983 biotransformation Effects 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
239000002775 capsule Substances 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
101150102523 cdc12 gene Proteins 0.000 description 1
ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
229960001076 chlorpromazine Drugs 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
229940125904 compound 1 Drugs 0.000 description 1
230000001143 conditioned effect Effects 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
QTCANKDTWWSCMR-UHFFFAOYSA-N costic aldehyde Natural products C1CCC(=C)C2CC(C(=C)C=O)CCC21C QTCANKDTWWSCMR-UHFFFAOYSA-N 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 1
HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
WTVNFKVGGUWHQC-UHFFFAOYSA-N decane-2,4-dione Chemical compound CCCCCCC(=O)CC(C)=O WTVNFKVGGUWHQC-UHFFFAOYSA-N 0.000 description 1
238000010586 diagram Methods 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
238000006073 displacement reaction Methods 0.000 description 1
239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
239000008298 dragée Substances 0.000 description 1
206010013781 dry mouth Diseases 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
230000003631 expected effect Effects 0.000 description 1
239000000284 extract Substances 0.000 description 1
239000000945 filler Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
235000011087 fumaric acid Nutrition 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
-1 heterocyclic carbon compound Chemical class 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
239000012442 inert solvent Substances 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
229940045996 isethionic acid Drugs 0.000 description 1
ISTFUJWTQAMRGA-UHFFFAOYSA-N iso-beta-costal Natural products C1C(C(=C)C=O)CCC2(C)CCCC(C)=C21 ISTFUJWTQAMRGA-UHFFFAOYSA-N 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
230000007721 medicinal effect Effects 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
238000002156 mixing Methods 0.000 description 1
238000000465 moulding Methods 0.000 description 1
230000003551 muscarinic effect Effects 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
239000012053 oil suspension Substances 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
230000001151 other effect Effects 0.000 description 1
230000001590 oxidative effect Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
235000011007 phosphoric acid Nutrition 0.000 description 1
150000003016 phosphoric acids Chemical class 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
210000002381 plasma Anatomy 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
239000000843 powder Substances 0.000 description 1
235000019260 propionic acid Nutrition 0.000 description 1
239000004089 psychotropic agent Substances 0.000 description 1
230000000506 psychotropic effect Effects 0.000 description 1
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
230000000862 serotonergic effect Effects 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
235000017550 sodium carbonate Nutrition 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
230000003595 spectral effect Effects 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
238000003756 stirring Methods 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000725 suspension Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000001308 synthesis method Methods 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
150000003568 thioethers Chemical class 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
239000003204 tranquilizing agent Substances 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Biomedical Technology (AREA)
Public Health (AREA)
Psychiatry (AREA)
Anesthesiology (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

LU86405A 1985-04-24 1986-04-23 Derive antipsychotique du benzisothiazole s-oxyde LU86405A1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US06/726,449 US4656173A (en)	1985-04-24	1985-04-24	Antipsychotic benzisothiazole S-oxide compound
US72644985		1985-04-24

Publications (1)

Publication Number	Publication Date
LU86405A1 true LU86405A1 (fr)	1986-11-05

Family

ID=24918649

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LU86405A LU86405A1 (fr)	1985-04-24	1986-04-23	Derive antipsychotique du benzisothiazole s-oxyde

Country Status (26)

Country	Link
US (1)	US4656173A (de)
JP (1)	JPH0764842B2 (de)
KR (1)	KR900000372B1 (de)
CN (1)	CN1017528B (de)
AT (1)	AT394719B (de)
AU (1)	AU592787B2 (de)
BE (1)	BE904662A (de)
CA (1)	CA1247102A (de)
CH (1)	CH666034A5 (de)
DE (1)	DE3613739C2 (de)
DK (1)	DK187686A (de)
EG (1)	EG18002A (de)
ES (1)	ES8708228A1 (de)
FI (1)	FI84604C (de)
FR (1)	FR2581064B1 (de)
GB (1)	GB2174393B (de)
GR (1)	GR861063B (de)
HU (1)	HU195654B (de)
IE (1)	IE59182B1 (de)
IT (1)	IT1208600B (de)
LU (1)	LU86405A1 (de)
MY (1)	MY102041A (de)
NL (1)	NL8601043A (de)
PT (1)	PT82450B (de)
SE (1)	SE462163B (de)
ZA (1)	ZA861531B (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4780466A (en) *	1988-03-17	1988-10-25	Hoechst-Roussel Pharmaceuticals, Inc.	Arylpiperazinylalkoxy derivatives of cyclic imides
EP0350145A3 (de) *	1988-04-28	1990-07-04	Yamanouchi Pharmaceutical Co. Ltd.	Pyridylthiazolidine carboxamide Derivative und ihreZwischenprodukte und deren Herstellung
WO1990002552A1 (en) *	1988-09-16	1990-03-22	Pfizer Inc.	Antipsychotic 4-[4-(3-benzisothiazolyl)-1-piperazinyl]butyl bridged bicyclic imides
US4956368A (en) *	1989-07-24	1990-09-11	Bristol-Myers Company	Metabolites and prodrug formulations of 8-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl]-8-azaspiro[4.5]decane-7,9-dione
US4968792A (en) *	1989-09-25	1990-11-06	American Home Products Corporation	Psychotropic benzisothiazole derivatives
US5162321A (en) *	1989-12-20	1992-11-10	Adir Et Compagnie	1-naphthyl piperazines useful as 5-HT1A receptor ligands
JP2800953B2 (ja) *	1990-07-06	1998-09-21	住友製薬株式会社	新規なイミド誘導体
JP6440625B2 (ja)	2012-11-14	2018-12-19	ザ・ジョンズ・ホプキンス・ユニバーシティー	精神分裂病を処置するための方法および組成物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BE759371A (fr) *	1969-11-24	1971-05-24	Bristol Myers Co	Azaspirodecanediones heterocycliques et procedes pour leur preparation
US3976776A (en) *	1972-12-06	1976-08-24	Mead Johnson & Company	Tranquilizer process employing N-(heteroarcyclic)piperazinylalkylazaspiroalkanediones
CH582699A5 (de) *	1973-03-26	1976-12-15	Sandoz Ag
AT342057B (de) *	1974-04-25	1978-03-10	Thomae Gmbh Dr K	Verfahren zur herstellung von neuen 3-piperazino-isochinolinen und deren salzen
FI753625A7 (de) *	1975-01-06	1976-07-07	Spofa Vereinigte Pharma Werke
JPS51144735A (en) *	1975-06-06	1976-12-13	Nippon Nohyaku Co Ltd	A remedy for hepatic failure
US4411901A (en) *	1981-12-23	1983-10-25	Mead Johnson & Company	Benzisothiazole and benzisoxazole piperazine derivatives
US4452799A (en) *	1981-12-23	1984-06-05	Mead Johnson & Company	Benzisothiazole and benzisoxazole piperazine derivatives
US4524206A (en) *	1983-09-12	1985-06-18	Mead Johnson & Company	1-Heteroaryl-4-(2,5-pyrrolidinedion-1-yl)alkyl)piperazine derivatives

1985
- 1985-04-24 US US06/726,449 patent/US4656173A/en not_active Expired - Lifetime
1986
- 1986-02-21 CA CA000502439A patent/CA1247102A/en not_active Expired
- 1986-02-28 ZA ZA861531A patent/ZA861531B/xx unknown
- 1986-04-02 KR KR1019860002515A patent/KR900000372B1/ko not_active Expired
- 1986-04-15 AU AU56121/86A patent/AU592787B2/en not_active Ceased
- 1986-04-20 EG EG232/86A patent/EG18002A/xx active
- 1986-04-21 FI FI861668A patent/FI84604C/fi not_active IP Right Cessation
- 1986-04-22 GR GR861063A patent/GR861063B/el unknown
- 1986-04-22 FR FR8605789A patent/FR2581064B1/fr not_active Expired
- 1986-04-23 SE SE8601883A patent/SE462163B/sv not_active IP Right Cessation
- 1986-04-23 CN CN86102742A patent/CN1017528B/zh not_active Expired
- 1986-04-23 PT PT82450A patent/PT82450B/pt not_active IP Right Cessation
- 1986-04-23 ES ES554284A patent/ES8708228A1/es not_active Expired
- 1986-04-23 IT IT8620187A patent/IT1208600B/it active
- 1986-04-23 LU LU86405A patent/LU86405A1/fr unknown
- 1986-04-23 GB GB08609932A patent/GB2174393B/en not_active Expired
- 1986-04-23 DK DK187686A patent/DK187686A/da not_active Application Discontinuation
- 1986-04-23 IE IE108386A patent/IE59182B1/en not_active IP Right Cessation
- 1986-04-23 BE BE0/216581A patent/BE904662A/fr not_active IP Right Cessation
- 1986-04-23 DE DE3613739A patent/DE3613739C2/de not_active Expired - Fee Related
- 1986-04-23 CH CH1685/86A patent/CH666034A5/de not_active IP Right Cessation
- 1986-04-23 NL NL8601043A patent/NL8601043A/nl active Search and Examination
- 1986-04-24 HU HU861704A patent/HU195654B/hu not_active IP Right Cessation
- 1986-04-24 JP JP61095859A patent/JPH0764842B2/ja not_active Expired - Lifetime
- 1986-04-24 AT AT0110486A patent/AT394719B/de not_active IP Right Cessation
1987
- 1987-09-28 MY MYPI87002086A patent/MY102041A/en unknown

Also Published As

Publication number	Publication date
NL8601043A (nl)	1986-11-17
AT394719B (de)	1992-06-10
SE8601883L (sv)	1986-10-25
GB8609932D0 (en)	1986-05-29
DE3613739A1 (de)	1986-11-20
GR861063B (en)	1986-09-01
JPH0764842B2 (ja)	1995-07-12
KR860008174A (ko)	1986-11-12
SE462163B (sv)	1990-05-14
FI861668A0 (fi)	1986-04-21
MY102041A (en)	1992-02-29
GB2174393A (en)	1986-11-05
FI84604B (fi)	1991-09-13
ES554284A0 (es)	1987-10-01
ZA861531B (en)	1986-10-29
ES8708228A1 (es)	1987-10-01
CA1247102A (en)	1988-12-20
JPS61251683A (ja)	1986-11-08
ATA110486A (de)	1991-11-15
AU592787B2 (en)	1990-01-25
FR2581064B1 (fr)	1988-09-16
DE3613739C2 (de)	1993-12-09
BE904662A (fr)	1986-10-23
CH666034A5 (de)	1988-06-30
AU5612186A (en)	1986-10-30
DK187686A (da)	1986-10-25
FI861668L (fi)	1986-10-25
GB2174393B (en)	1989-02-01
US4656173A (en)	1987-04-07
CN1017528B (zh)	1992-07-22
IE59182B1 (en)	1994-01-26
FR2581064A1 (fr)	1986-10-31
HUT42088A (en)	1987-06-29
KR900000372B1 (ko)	1990-01-25
HU195654B (en)	1988-06-28
DK187686D0 (da)	1986-04-23
PT82450B (pt)	1988-11-30
IE861083L (en)	1986-10-24
IT1208600B (it)	1989-07-10
SE8601883D0 (sv)	1986-04-23
FI84604C (fi)	1991-12-27
IT8620187A0 (it)	1986-04-23
PT82450A (en)	1986-05-01
EG18002A (en)	1991-08-30
CN86102742A (zh)	1987-02-04

Publication	Publication Date	Title
EP0497659B1 (de)	1996-04-10	Aryl(oder Heteroaryl)-piperazinyl-alkyl-azol-derivate, ihre Herstellung und ihre Anwendung als Medikament
EP0506532B1 (de)	1994-09-07	Indolderivate, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
EP1309594B1 (de)	2004-12-15	Benzimidazolderivate, ihre herstellung und therapeutische verwendung
EP0850235B1 (de)	1999-12-01	Chinolin-2-on derivate als serotonin antagonisten
EP0202164B1 (de)	1989-02-08	(Benzoyl-4-piperidino)-2-phenyl-1-alkanolderivate, ihre Herstellung und ihre Verwendung als Heilmittel
EP0501892B1 (de)	1996-07-24	Diazotierte heterocyclische Derivate aus Stickstoff, substituiert durch eine Biphenylgruppe, ihre Herstellung, und diese enthaltende pharmazeutische Zubereitungen
LU84011A1 (fr)	1983-02-22	2-phenoxyalkyl-1,2,4-triazol-3-ones antidepressives
LU79761A1 (fr)	1980-01-22	Procede de preparation de nouveaux composes de phtalazine et de composition pharmaceutique les contenant
EP0557171A1 (de)	1993-08-25	Azaindole, deren Herstellungsverfahren und sie enthaltende Arzneimittel
CH639653A5 (fr)	1983-11-30	Aminothiazoles et composition pharmaceutique les contenant.
EP0429341A2 (de)	1991-05-29	Heterocyclische Derivate, ihre Herstellung und sie enthaltende Arzneimittel
LU85561A1 (fr)	1985-06-04	1,2,4-triazol-3-ones,antidepressives
EP0623138B1 (de)	1997-05-21	Adenosinderivate, Verfahren zu deren Herstellung und pharmazeutische Mittel
LU86405A1 (fr)	1986-11-05	Derive antipsychotique du benzisothiazole s-oxyde
EP0429360A2 (de)	1991-05-29	Verhinderung von Entzugserscheinungen
FR2717810A1 (fr)	1995-09-29	Nouvelles aminoalkyl benzoxazolinones et benzothiazolinones, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
EP0463944B1 (de)	1994-10-05	Acylbenzoxazolinone, Verfahren zu ihrer Herstellung und pharmazeutische Zusammensetzungen die sie enthalten
FR2584408A1 (fr)	1987-01-09	Derives diazinylpiperidiniques d'amines et d'imides cycliques a application psychogeriatrique
EP0385848A1 (de)	1990-09-05	Benzoxazolinon-Derivate, Verfahren zu deren Herstellung und pharmazeutische Zusammensetzungen, die sie enthalten
CH661271A5 (fr)	1987-07-15	Derives de piperazine et d'homopiperazine, leurs procedes de preparation et les compositions pharmaceutiques les renfermant.
EP1966173B1 (de)	2010-11-17	Heterocyclische derivate, deren herstellung und therapeutische verwendung
FR2753970A1 (fr)	1998-04-03	Derives de n-(benzothiazol-2-yl) piperidine-1-ethanamine, leur preparation et leur application en therapeutique
WO1991016323A1 (fr)	1991-10-31	Derives du naphtosultame antagonistes de la serotonine, leur preparation et les medicaments les contenant
CA2346506C (fr)	2009-01-13	Derives d'aryl-{4-fluoro-4-[(2-pyridin-2-yl-ethylamino)-methyl]-piperidin-1-yl}-methanone comme agonistes du recepteur 5-ht1
CA1263862A (fr)	1989-12-12	Derives d'amino-5 pentanenitrile et leur procede de preparation